AFYA LIMITED (AFYA): what the price assumes

boothcheck covers AFYA LIMITED (AFYA) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-07-25.

Generated: 2026-08-30 · Exported: 2026-08-31 · Source: https://boothcheck.com/report/AFYA

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 6: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 7.2% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: n/a

Valuation X-Ray

The price is supported by asset-based and earnings-power and relative-multiple and growth-DCF value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Asset, Earnings, Relative, Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 10.3%); the inversion above states its own rate.

Per-Model Detail (n=17)

Solvency

Bullet Takeaways

• Afya owns the scarce asset in Brazilian medical education, government-authorized medical school seats, and states in its own filing that based on our number of MEC's approved medical seats, as compared to our main competitors, we have the largest medical education footprint in Brazil.
• The whole company changes hands for roughly seven times its operating profit, a level that would ordinarily be attached to a business in decline, while enrolment grew to 86,025 enrolled students at the end of 2025 from 76,988 a year earlier.
• The constraint to watch is the interest bill rather than the customer: operating profit covers interest only a little over two times, and Brazilian borrowing costs sit far above anything the American peer group pays.

Bull Case

The direction of travel is the argument here. Revenue for 2025 reached R$3,697.3 million, an increase of R$393.0 million, or 11.9% over 2024, and the profit rose faster than the revenue did. Gross profit came in at R$2,383.4 million, an increase of R$294.7 million, or 14.1%, because the cost of delivering the teaching grew more slowly than the tuition being charged: cost of services rose 8.1% and fell as a share of revenue to 35.5%. Step back one more year and the pattern is the same, with operating income for 2024 at R$1,012.1 million, an increase of R$245.0 million, or 31.9%. This is a business whose margin has been widening for several years while the top line compounds at a low double-digit rate.

Where it ends up puts Afya at the top of its comparison group. About 32.8% of each revenue dollar reaches operating profit, against 24.3% at Perdoceo, 24.3% at Grand Canyon Education, 24.0% at Laureate, 15.8% at Stride and 13.8% at Strategic Education. Afya also grew faster than all of them. Earning the highest margin in a cohort while also posting the fastest growth is rare enough that it usually signals something structural rather than something cyclical.

The structure in this case is a licence. Brazilian medical schools cannot simply expand; every seat requires authorization from the education ministry, and the filing spells out how tight the bottleneck is, describing the requirement of the availability of public hospital beds within Brazil's Unified Health System (SUS) for medical practice scenarios and noting that the ministry has, from time to time, restricted, suspended and revised the authorization of new medical education courses. Afya holds more approved seats than anyone else in the country. That is not a brand advantage that a competitor can out-market; it is a permit inventory that a competitor has to petition the government to obtain. American operators in the peer group describe a different world entirely, one where Strategic Education faces increasing competition for students from traditional colleges and Grand Canyon Education warns that competitors could divert university partners. Nobody diverts a medical school seat.

The regulatory shape improved in the company's favour in early 2026. The ministry had opened a public call under the Mais Médicos programme that provided for the potential opening of up to approximately 5,700 new undergraduate seats, to be distributed across 95 cities with a limit of 60 seats per institution, and then, on February 10, 2026, MEC formally cancelled the public call. Roughly 5,700 potential competing seats stopped being a threat on a single Tuesday. Meanwhile Afya kept adding its own through acquisition, with the Unidom purchase contributing 300 operational medical school seats to the Undergraduate segment.

Underneath the medical schools sits a smaller business that is quietly interesting. The medical practice solutions line grew to 195,504 active paying users in 2025, selling software and continuing education to the doctors the undergraduate segment trained. It is only a few percent of revenue today. It is also the closest thing here to a recurring subscription attached to a customer the company already knows by name.

Bear Case

Look at the capital structure before looking at anything else, because it explains more about this stock than the enrolment numbers do. Operating profit covers the interest bill only a little over two times. For a company earning a third of its revenue as operating profit, that is a startling ratio, and it exists because the debt is Brazilian and priced off Brazilian policy rates. The 20-F puts loans and financing at 2,054,267 thousand reais at the end of 2025 alongside lease liabilities of 1,065,746 thousand, and campuses are leased, so the lease line is a fixed obligation in every practical sense. A business with this shape has plenty of room while rates and enrolment cooperate. It has considerably less room if either stops.

The acquisitions are what make that arithmetic matter. Growth here has been partly bought rather than grown: the Unidom deal alone required cash paid net of cash acquired with the subsidiary 337,501 thousand reais, and the seats it brought were still awaiting authorization approval. Every acquisition of this kind converts balance-sheet capacity into future revenue that depends on a regulator saying yes. When the interest bill already consumes a large share of operating profit, the margin for a deal that does not convert on schedule is thin.

The regulator is the second structural exposure and it cuts in both directions. Investors who cheer the cancellation of the Mais Médicos public call should notice what the cancellation actually demonstrates, which is that the ministry can rewrite the competitive landscape in either direction without warning and did so in February 2026. The filing is explicit that the ministry has, from time to time, restricted, suspended and revised the authorization of new medical education courses, and the regulatory framework governing the opening of new medical courses has also been subject to constitutional review, and that programs receiving unsatisfactory evaluations may be subject to an administrative supervisory proceeding by MEC. Afya's scarcity is granted by an authority that can also grant it to somebody else. It also warns that factors affecting the amount of tuition fees we are able to charge or the ability of our students to pay such tuition fees could cut demand sharply, which is the polite way of saying that medical tuition in Brazil is expensive relative to household income and financed accordingly.

Then there is currency, which quietly distorts how good the last year looks. Reported in reais the 2025 revenue increase was 11.9%. Translated into dollars the same year reads considerably better, because the real strengthened. An American holder of these shares owns a stream of reais and is exposed to the exchange rate in both directions, and the filing treats both a devaluation and an appreciation of the real as capable of doing damage to the Brazilian economy the company sells into. None of the underlying growth is currency-driven, but a fair share of how the growth appears in dollars is.

The valuation objection is the subtlest one and it deserves stating properly. Most ways of measuring the business land above today's price, which is what makes the stock look inexpensive. The exception is the approach that values the company on a five-year average of operating income with one-off charges added back, assuming no growth at all. On that basis the price sits well above what the business supports, and the reason is that the margin expansion is recent. If the last three years of widening margin turn out to have been a phase rather than a level, the cheapness disappears and what is left is a leveraged, regulated, single-country operator trading roughly where it should.

Valuation

The starting fact is unusual enough to state on its own. The entire company is priced at roughly seven times its operating profit, which is below what a business shrinking its operating profit by 5% a year would warrant. The market is not asking Afya to grow. It is pricing in decline, and the company keeps reporting the opposite, with enrolment up to 86,025 students at the end of 2025 and local-currency revenue still compounding at a low double-digit pace.

That gap shows up consistently across the methods used to triangulate the value. Every family of approach lands above the current price. Approaches based on book value and returns on it land roughly a third above; approaches based on current earning power land above by a bit more than that; peer multiples land close to double the price; and the cash-flow approaches land highest of all. When no standard method thinks the price is expensive, the honest interpretation is not that the market has made an arithmetic error. It is that the market is applying a discount the methods do not contain: Brazilian country risk, a regulated licence base, and a leveraged balance sheet in a high-rate currency.

One approach dissents, and it is the one worth engaging. Valuing the company on a normalized five-year average of operating income with one-time charges added back, and assuming no growth whatever, produces a figure well below today's price. The dissent is informative rather than contradictory. It says the recent margin is better than the average margin, which is a fact the trajectory already told us. The question that follows is whether the current level is the new normal or the top of a cycle, and the answer determines which of the two readings is right.

The comparison group makes the discount visible in a different way. Afya converts about 32.8% of revenue into operating profit, higher than Perdoceo, Grand Canyon Education and Laureate at roughly 24% each, and it grew faster than any of them, with Laureate at 13.8% and Perdoceo at 17.7% revenue growth against Afya's low-double-digit local-currency pace. Same industry, better operating numbers, materially lower multiple. The difference is jurisdiction and financing, not operations.

Which brings the section to where a buyer's actual risk sits. This is not a company with a liquidity problem, and the share count has been essentially stable, drifting down about 0.8% a year over four years. What it has instead is a fixed-charge load that leaves operating profit covering interest only a bit more than twice over, in a country whose policy rate sets the cost of that debt. The cheapness is real, and so is the reason for it.

Catalysts

The most consequential recent development was not an earnings print. On February 10, 2026, the education ministry formally cancelled the public call under the Mais Médicos programme that would have authorized up to roughly 5,700 new undergraduate medical seats across 95 cities. For an operator whose competitive position rests on holding more approved seats than anyone else in Brazil, the removal of a potential nationwide seat auction changes the supply picture for years, not quarters. It also demonstrates how quickly the same ministry could change it back.

Afya has continued adding seats through the ordinary channel. The company received authorization on February 6, 2026 for 63 additional medical seats in Abaetetuba, bringing its portfolio to 3,768 approved medical seats. First-quarter results showed a fully occupied intake cycle at the medical schools, with net income of R$261.8 million, up 1.8% on the year, and management reaffirmed its 2026 guidance on the assumption that new student acceptance for the first semester completed as planned.

Capital return has started to feature. A dividend of R$307.4 million was approved in March 2026 based on 2025 earnings, and the board authorized share repurchases under conditions set in August 2025. Shareholders approved the 2025 financial statements at the annual general meeting held on June 22, 2026. For a company whose valuation debate turns on whether the recent margin level persists, the second-half intake cycle and the pace of that buyback are the two things that will move the argument.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• LAUR (Laureate Education, Inc.)
• FY2025 10-K: …the financial and operational support of local governments, have resulted in increased enrollments in private institutions relative to public institutions. Increasing Demand for Online Offerings. We believe that increasing student demand, new instruction methodologies designed for the online medium, and growing…
• FY2025 10-K: …higher education in Mexico and Peru is highly fragmented and marked by large numbers of local competitors. The target demographics are primarily 18- to 24-year-olds in the countries in which we compete. Public institutions tend to be less expensive, if not free, but limited in capacity. The top public universities in…
• PRDO (Perdoceo Education Corporation)
• FY2025 10-K: …operations, such as the 90-10 Rule and GE. We have experienced increased competition as more postsecondary education providers increase their online program offerings (in particular programs that are geared towards the needs of working adults), including traditional and community colleges that had not previously…
• FY2025 10-K: …facing the for-profit postsecondary education industry may make it difficult to retain key personnel, in particular long-tenured senior officers. Loss of key personnel in the future could impact our growth, lead to changes in or create uncertainty about our business strategies or otherwise impact management's…
• STRA (Strategic Education, Inc.)
• FY2025 10-K: …learning modalities, we face increasing competition for students from traditional colleges, including colleges with well-established reputations for excellence and colleges in states that offer various forms of "free college" programs. As online learning matures as a modality for education delivery across higher…
• FY2025 10-K: …is highly competitive and online education is subject to rapid technological change. We compete with traditional public and private two-year and four-year colleges, many of which have some form of online education programs, other for-profit schools, vocational education organizations, and other alternatives to higher…
• LOPE (Grand Canyon Education, Inc.)
• FY2025 10-K: …adverse impact on our future growth. We face competition from established and other emerging companies, which could divert university partners to our competitors, result in pricing pressure and significantly reduce our revenue. We expect existing competitors and new entrants to the educational services market to…
• FY2025 10-K: …develop new degree programs often delivered online, has historically been characterized by a full-service, revenue-sharing model, based on the premise that most traditional institutions are not only operationally unprepared to offer these programs at scale but also are not equipped to make the significant upfront…
• GHC (GRAHAM HOLDINGS CO)
• FY2025 10-K: …by Christopher J. Ourisman and his team of industry professionals. (6) Other segment items for each reportable segment include: (a) Education (includes Kaplan International, Kaplan Higher Education and Kaplan Supplemental Education) - training and employment expense, travel meals and entertainment expense, operating…
• FY2025 10-K: …revenue. (5) Management and operating services provided by Christopher J. Ourisman and his team of industry professionals. (6) Other segment items for each reportable segment include: (a) Education (includes Kaplan International, Kaplan Higher Education and Kaplan Supplemental Education) - training and employment…
• LRN (Stride, Inc.)
• FY2025 10-K: …In addition, some of our school-as-a-service offerings could seek to transition to a self-managed school by inviting competitive alternatives to portions of the products and services now provided entirely by us under our integrated fully managed service agreements. If we are unable to successfully compete for new…
• FY2025 10-K: …schools is inadequate, our opportunities for growth and our ability to sustain our revenues, results of operations and financial condition would be adversely affected. Increasing competition in the education industry sectors that we serve could lead to pricing pressures, reduced operating margins, loss of market…
• UTI (UNIVERSAL TECHNICAL INSTITUTE, INC)
• FY2025 10-K: …Title IV funding, including not-for-profit public and private schools, community colleges and for-profit institutions which offer programs similar to ours. Our competition differs in each market depending on the curriculum we offer and the availability of other choices, including job prospects. Other competitive…
• FY2025 10-K: …Competition is generally based on location, tuition rates, the type of programs offered, the quality of instruction and instructional facilities, graduate employment rates, reputation and recruiting. Additionally, the military often recruits or retains potential students when branches of the military offer enlistment…
• TAL (TAL Education Group)
• (no filing in the citation store)

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.